AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
AtriCure, Inc.
Video analysis: ATRC
All videosNo video analysis for this stock yet. Request one from our team.
News: ATRC
AtriCure CTO Sells 3,657 Shares
The transaction was valued at $201,000. The sale represented 2% of the insider's direct equity holdings prior to the transaction.
Do Options Traders Know Something About AtriCure Stock We Don't?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?
AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time. Interested parties may a.
AtriCure: Promising Cardiovascular Surgical Platform
AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.
A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95
On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a strong performance in the market. Over the past week, the s
